Published in Kidney Int on March 01, 1988
Hypertension and impaired renal function accompany juvenile obesity: the effect of prenatal diet. Kidney Int (2007) 1.56
The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol (2004) 1.45
3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/ p21 signaling pathway: Implications for diabetic nephropathy. Proc Natl Acad Sci U S A (2002) 1.41
Novel pharmacological approaches to the treatment of renal ischemia-reperfusion injury: a comprehensive review. Naunyn Schmiedebergs Arch Pharmacol (2007) 1.35
PPARalpha: an emerging therapeutic target in diabetic microvascular damage. Nat Rev Endocrinol (2010) 1.34
Relation of serum lipids and lipoproteins with progression of CKD: The CRIC study. Clin J Am Soc Nephrol (2014) 1.10
Nondiabetic consequences of obesity on kidney. Pediatr Nephrol (2006) 1.07
Hypercholesterolemia and microvascular dysfunction: interventional strategies. J Inflamm (Lond) (2010) 1.06
Proximal tubule angiotensin AT2 receptors mediate an anti-inflammatory response via interleukin-10: role in renoprotection in obese rats. Hypertension (2013) 1.05
Saturated free fatty acids and apoptosis in microvascular mesangial cells: palmitate activates pro-apoptotic signaling involving caspase 9 and mitochondrial release of endonuclease G. Cardiovasc Diabetol (2005) 0.93
Antibodies reactive to non-HLA antigens in transplant glomerulopathy. J Am Soc Nephrol (2011) 0.91
Lovastatin inhibits proliferation of rat mesangial cells. J Clin Invest (1993) 0.87
An evaluation of experimental models of glomerulonephritis. Int J Exp Pathol (1994) 0.84
Effects of atorvastatin on progression of diabetic nephropathy and local RAGE and soluble RAGE expressions in rats. J Zhejiang Univ Sci B (2011) 0.84
An update on 'progression promoters' in renal diseases. J Natl Med Assoc (2003) 0.84
Statin-Induced Increase in HDL-C and Renal Function in Coronary Heart Disease Patients. Open Cardiovasc Med J (2007) 0.82
Podocyte injury-driven lipid peroxidation accelerates the infiltration of glomerular foam cells in focal segmental glomerulosclerosis. Am J Pathol (2015) 0.81
Dyslipoproteinemia and impairment of renal function in diabetic kidney disease: an analysis of animal studies, observational studies, and clinical trials. Rev Diabet Stud (2013) 0.81
Renal apolipoproteins in nephrotic rats. Am J Pathol (1993) 0.80
Caloric restriction or telmisartan control dyslipidemia and nephropathy in obese diabetic Zücker rats. Diabetol Metab Syndr (2014) 0.79
Vasopeptidase inhibition attenuates proteinuria and podocyte injury in Zucker diabetic fatty rats. Naunyn Schmiedebergs Arch Pharmacol (2007) 0.78
Antiproliferative effect of fluvastatin and thiazolidinedione in mesangial cells of diabetic rats. Pediatr Nephrol (2003) 0.76
Antiretroviral therapy-induced changes in plasma lipids and the risk of kidney dysfunction in HIV-infected men. AIDS Res Hum Retroviruses (2013) 0.75
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med (2001) 22.32
Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet (1995) 4.06
Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch Intern Med (1989) 2.94
Identification of the CD4(+) T cell as a major pathogenic factor in ischemic acute renal failure. J Clin Invest (2001) 2.79
Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis (1999) 2.38
Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother (1984) 2.09
Definition of health promotion: Part III: Expanding the definition. Am J Health Promot (1989) 1.95
The glomerular mesangium. Kidney Int (1980) 1.83
Experimental pyelonephritis. XIV. Pyelonephritis in normal mice produced by inoculation of E. coli into the bladder lumen during water diuresis. Yale J Biol Med (1967) 1.67
The laryngeal mask airway and positive-pressure ventilation. Anesthesiology (1994) 1.62
Mechanism of Escherichia coli alpha-hemolysin-induced injury to isolated renal tubular cells. Am J Pathol (1987) 1.57
Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med (1993) 1.54
Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients. Ann Intern Med (1994) 1.44
Antimicrobial treatment of peritonitis associated with continuous ambulatory peritoneal dialysis. Perit Dial Int (1991) 1.42
A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18. Cytokine (2001) 1.41
Bacterial growth and killing in chronic ambulatory peritoneal dialysis fluids. J Clin Microbiol (1984) 1.36
The losartan renal protection study--rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). J Renin Angiotensin Aldosterone Syst (2000) 1.35
Effects of adiponectin on breast cancer cell growth and signaling. Br J Cancer (2008) 1.35
Peritoneal macrophages and opsonins: antibacterial defense in patients undergoing chronic peritoneal dialysis. J Infect Dis (1983) 1.35
Cefotaxime and desacetyl cefotaxime kinetics in renal impairment. Clin Pharmacol Ther (1985) 1.34
Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction? Lancet (1996) 1.34
Opsonic deficiency of peritoneal dialysis effluent in continuous ambulatory peritoneal dialysis. Kidney Int (1984) 1.29
Proteinuria is a risk factor for mortality over 10 years of follow-up. MRFIT Research Group. Multiple Risk Factor Intervention Trial. Kidney Int Suppl (1997) 1.28
Obesity is associated with a decreased leptin transport across the blood-brain barrier in rats. Diabetes (2000) 1.26
Renal injury of diet-induced hypercholesterolemia in rats. Kidney Int (1990) 1.21
Ethylene glycol poisoning: pharmacokinetics during therapy with ethanol and hemodialysis. N Engl J Med (1981) 1.21
Gas leak and gastric insufflation during controlled ventilation: face mask versus laryngeal mask airway. Can J Anaesth (1998) 1.20
The Zucker rat model of obesity, insulin resistance, hyperlipidemia, and renal injury. Hypertension (1992) 1.20
Current concepts in the management of peritonitis in patients undergoing continuous ambulatory peritoneal dialysis. Rev Infect Dis (1987) 1.19
Developmental changes in thymidine kinase, DNA, and fat cellularity in Zucker rats. Am J Physiol (1979) 1.16
Development of obesity in Zucker obese (fafa) rat in absence of hyperphagia. Am J Physiol (1980) 1.13
Survival and rehabilitation of patients on home hemodialysis. Five years' experience. Ann Intern Med (1973) 1.13
Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure. Circ Res (1988) 1.13
Opioid-mediated suppression of interferon-gamma production by cultured peripheral blood mononuclear cells. J Clin Invest (1987) 1.09
Inhibition of ultraviolet B-induced activator protein-1 (AP-1) activity by aspirin in AP-1-luciferase transgenic mice. J Biol Chem (1997) 1.08
Intracellular survival of Candida albicans in peritoneal macrophages from chronic peritoneal dialysis patients. Am J Kidney Dis (1986) 1.08
Enhancement of endotoxin-induced isolated renal tubular cell injury by toxic shock syndrome toxin 1. Am J Pathol (1986) 1.04
Incidence and type of infections occurring in 445 chronic hemodialysis patients. Trans Am Soc Artif Intern Organs (1977) 1.03
Sequential changes in the activities of lipoprotein lipase and lipogenic enzymes during tumor growth in rats. Cancer Res (1984) 1.02
Recent advances in statins and the kidney. Kidney Int Suppl (1999) 1.01
Vitamin A during lactation: relationship of maternal diet to milk vitamin A content and to the vitamin A status of lactating rats and their pups. J Nutr (1985) 1.01
Disposition of gabapentin in anuric subjects on hemodialysis. J Clin Pharmacol (1995) 0.99
Glomerular hemodynamic and structural alterations in experimental diabetes mellitus. FASEB J (1988) 0.98
Opioid peptides rapidly stimulate superoxide production by human polymorphonuclear leukocytes and macrophages. Endocrinology (1985) 0.98
Opioid-mediated suppression of cultured peripheral blood mononuclear cell respiratory burst activity. J Immunol (1987) 0.98
Unilateral Shwartzman reaction: cortical necrosis in one kidney following in vivo perfusion with endotoxin. Kidney Int (1977) 0.98
Effects of genetic obesity on renal structure and function in the Zucker rat. J Lab Clin Med (1985) 0.96
Pharmacokinetics of tazobactam M1 metabolite after administration of piperacillin/tazobactam in subjects with renal impairment. J Clin Pharmacol (1994) 0.96
Role of hypertension in progressive glomerular immune injury. Hypertension (1985) 0.96
Hyperlipidemia and the progression of renal disease. Am J Clin Nutr (1988) 0.96
Relationship among altered glomerular barrier permselectivity, angiotensin II, and mesangial uptake of macromolecules. Lab Invest (1985) 0.95
Protein binding of disopyramide and elevated alpha-1-acid glycoprotein concentrations in serum obtained from dialysis patients and renal transplant recipients. Am J Nephrol (1985) 0.95
Effect of lovastatin on the development of polycystic kidney disease in the Han:SPRD rat. Am J Kidney Dis (1995) 0.95
Early glomerular changes in rats with dietary-induced hypercholesterolemia. Am J Kidney Dis (1995) 0.93
Cholesterol-lowering effects of calcium carbonate in patients with mild to moderate hypercholesterolemia. Arch Intern Med (1992) 0.92
Lovastatin but not enalapril reduces glomerular injury in Dahl salt-sensitive rats. Hypertension (1992) 0.92
Lipids and progressive glomerulosclerosis. A model analogous to atherosclerosis. Am J Nephrol (1988) 0.92
Opsonization of Legionella pneumophila in human serum: key roles for specific antibodies and the classical complement pathway. Immunology (1985) 0.91
Anti-obesity effect of two different levels of dehydroepiandrosterone in lean and obese middle-aged female Zucker rats. Int J Obes (1986) 0.91
Small molecule selectin ligand inhibition improves outcome in ischemic acute renal failure. Kidney Int (2001) 0.90
Effects of genetic obesity on renal structure and function in the Zucker rat. II. Micropuncture studies. J Lab Clin Med (1985) 0.90
Polyamino acid enhancement of bacterial phagocytosis by human polymorphonuclear leukocytes and peritoneal macrophages. Infect Immun (1984) 0.89
Lovastatin retards the progression of established glomerular disease in obese Zucker rats. Am J Kidney Dis (1993) 0.89
Central role of the transcription factor nuclear factor-kappa B in mesangial cell production of chemokines. Contrib Nephrol (1997) 0.88
Effect of (-)-hydroxycitrate on development of obesity in the Zucker obese rat. Am J Physiol (1981) 0.88
Adriamycin-induced chronic proteinuria: a structural and functional study. J Lab Clin Med (1985) 0.88
Alterations in lipogenic enzymes and lipoprotein lipase activity during gram-negative sepsis in the rat. Arch Surg (1982) 0.88
Lovastatin inhibits proliferation of rat mesangial cells. J Clin Invest (1993) 0.87
Lipid abnormalities in end stage renal disease. Nephrol Dial Transplant (1998) 0.87
Antimicrobial activities of dialysate-elicited and resident human peritoneal macrophages. Infect Immun (1985) 0.87
Forces shaping the future of health promotion. Am J Health Promot (2001) 0.87
Renal cell cytokine production stimulates HIV-1 expression in chronically HIV-1-infected monocytes. Kidney Int (1998) 0.87
Development of food motivated behavior in free feeding and food restricted Zucker fatty (fa/fa) rats. Physiol Behav (1980) 0.86
Low-density lipoprotein-induced expression of interleukin-6, a marker of human mesangial cell inflammation: effects of oxidation and modulation by lovastatin. Biochem Biophys Res Commun (2000) 0.86
Cefsulodin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother (1983) 0.86
The relationship between modifiable health risks and future medical care expenditures: the Korea Medical Insurance Corporation (KMIC) Study. Am J Health Promot (2001) 0.86
Mononuclear phagocytic system stimulation. Protective role from glomerular immune complex deposition. J Lab Clin Med (1981) 0.86
Hyperlipidemia in the nephrotic syndrome. N Engl J Med (1990) 0.86
Lovastatin reduces glomerular macrophage influx and expression of monocyte chemoattractant protein-1 mRNA in nephrotic rats. Am J Kidney Dis (1998) 0.85
Teicoplanin pharmacokinetics in patients undergoing continuous ambulatory peritoneal dialysis after intravenous and intraperitoneal dosing. Antimicrob Agents Chemother (1989) 0.85
The central role of nuclear factor-kappa B in mesangial cell activation. Kidney Int Suppl (1999) 0.85
Lovastatin inhibits lipopolysaccharide-induced NF-kappaB activation in human mesangial cells. Nephrol Dial Transplant (1996) 0.85
Perinephric abscess in patients with polycystic kidney disease undergoing chronic hemodialysis. Nephron (1979) 0.85
Impaired mesangial clearance of macromolecules in rats with chronic mesangial ferritin-antiferritin immune complex deposition. Lab Invest (1980) 0.85